Presentation Information
[O-04-6]Self-administration of rozanolixizumab in generalized myasthenia gravis: MG0020 study
Genya Watanabe1,11, Carlo Antozzi2,11, Tomasz Berkowicz3,11, Vera Bril4,11, Artur Druzdz5,11, Rachana K. Gandhi Mehta6,11, Zabeen K. Mahuwala7,11, Jana Zschüntzsch8,11, Marion Boehnlein9, Andreea Lavrov9, Mark Morris9, Puneet Singh9, M. Isabel Leite10,11, MG0020 study team11 (1.Department of Neurology, National Hospital Organization Sendai Medical Center, Japan, 2.Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Italy, 3.Miejskie Centrum Medyczne JONSCHER, Poland, 4.University Health Network, Toronto, Canada, 5.Department of Neurology, Municipal Hospital, Poland, 6.Department of Neurology, Wake Forest University School of Medicine, USA, 7.Department of Neuromuscular Medicine, Epilepsy and Clinical Neurophysiology, University of Kentucky, USA, 8.Department of Neurology, University Medical Center Göttingen, Germany, 9.UCB, Other country, 10.Nuffield Department of Clinical Neurosciences, University of Oxford, UK, 11.MG0020 study team)